Clay Siegall’s Relentless Efforts To Fight Cancer Through Seattle Genetics

Clay Siegall is a prominent scientist who is reputable for his remarkable contributions in the field of cancer research. His deep passion of helping others and undying desire to eradicate cancer saw him co-found Seattle Genetics in 1998. This biotechnology company focuses on the development and commercialization of innovative antibody-based cancer therapies. As the CEO of the corporation, Dr. Clay has exhibited unique leadership skills that have resulted in the development of cutting-edge products and services. Within five years of operations, the company’s stock tripled in value. Seattle Genetics is an industry leader owing to its great advancements in cancer research and creation of viable cancer therapies.

Clay played a pivotal role in the development of their first antibody-drug conjugate (ADCs). In 2011, he oversaw the approval of ADCETRIS by FDA. ADCETRIS is quickly gaining popularity in the market. It is now sold in over 60 countries across the world. Clay is determined to promote ADCETRIS to ensure that the medical community prioritizes cancer research with the objective of producing more drugs. Seattle Genetics has also embarked on expanding its product portfolio by developing a pipeline of more ADCs. In addition, Dr. Siegall has spearheaded the fundraising activities of the corporation to raise over $1.2 billion from private and public funding. They have used this capital to advance cancer research by incorporating the most innovative technology. The industry leader focuses on making new scientific achievements. Presently, Clay Siegall holds 15 patents.

After his graduation from George Washington University, Clay began his practice in medical research by working for Bristol-Myers Squibb Pharmaceutical Research Institute as a senior researcher. His hard work earned him a promotion to serve as a principal scientist before joining the National Cancer Institute as a staff and biotechnology fellow. He also served at the National Institutes of Health. Clay sits on the boards of Alder BioPharmaceuticals, Ultragenyx Pharmaceuticals and Washington Roundtable. In 2013, the University of Maryland honored Dr. Clay Siegall with the Alumnus of the Year award for Computer, Math and Natural Sciences. He is also a recipient of the 2012 Pacific Ernst & Young Entrepreneur of the Year. Clay has authored over 70 publications. He holds a PhD in Genetics and a B.S. in Zoology.